Drugs / RG2417
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00812058 | Nov 2008 → Dec 2010 | bipolar depression | Repligen Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG2417 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00812058 ↗ |
| Route | Oral | “Oral RG2417 taken twice daily for 8 weeks” NCT00812058 ↗ |